Investing

Prime Medicine : PRME

PRME

Stock Data

$3.41

$0.14 (3.81%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Prime Medicine Inc is a pioneering biotechnology firm based in Cambridge, Massachusetts, focused on advancing genetic therapies across a broad spectrum of diseases. Utilizing cutting-edge gene editing technology, Prime Medicine develops Prime Editors, innovative tools that enable precise DNA edits. These editors combine a Cas protein with a reverse transcriptase enzyme and a pegRNA for targeted action. The company is also exploring novel treatments for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome through a research partnership with Cimeio Therapeutics. Founded in 2019, Prime Medicine is at the forefront of genetic therapy innovation.

All Prime Medicine Articles

3 Articles

Trey Thoelcke | Aug 7, 2025 at 8:45 AM EDT

Berkshire Hathaway Picks Up More of Warren Buffett’s Favorite Media Stock

Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech…

Joshua Rodriguez | Oct 1, 2024 at 3:19 PM EDT

Got $100? Consider Buying These 2 Penny Stocks in October (PRME, RLX)

You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part of…

Trey Thoelcke | Feb 27, 2024 at 8:45 AM EST

Stock Offerings Prompt Big Insider Buying

Public offerings of stock tempted some insider buying, and one insider stepped up to support a struggling online delivery service…